← All trials
NCT05293236
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 14, 2022
- Primary completion
- Jan 31, 2023
- Completion date
- Jan 31, 2023
- First posted
- Mar 24, 2022
- Last posted
- Sep 29, 2022
- Enrollment
- 30
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- aptaTargets S.L.Lead sponsor
- Universidad Autonoma de MadridOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- aptaTargets S.L.Sponsor investigator
- aptaTargets S.L.Study director
- Universidad Complutense de MadridOfficial
- Universidad Autonoma de MadridOfficial
- aptaTargets S.L.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.